Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome.
暂无分享,去创建一个
A. Kirtane | D. Morrow | S. Murphy | N. Lakkis | H. Herrmann | D. Cohen | C. Gibson | I. Kosmidou | D. Karmpaliotis | J. Blankenship | L. Jennings | W. French | K. Ray | R. Kovach | T. Palabrica | Henry H Lui | D. Budiu | Henry H. Lui | David A. Morrow | Sabina A. Murphy | D. Cohen | Lisa K. Jennings | David J. Cohen | C. Gibson | Kausik K. Ray | C. Gibson | Ajay J. Kirtane | Howard C. Herrmann
[1] Y. Jang,et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. , 2005, The American journal of cardiology.
[2] S. Petersen,et al. Troponin Elevation After Percutaneous Coronary Intervention Directly Represents the Extent of Irreversible Myocardial Injury: Insights From Cardiovascular Magnetic Resonance Imaging , 2005, Circulation.
[3] E. Alegrı́a,et al. Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: effect of the -174 G/C IL-6 gene polymorphism. , 2004, The American journal of cardiology.
[4] V. Pasceri,et al. Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study , 2004, Circulation.
[5] D. Yellon,et al. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. , 2003, Journal of the American College of Cardiology.
[6] M. Bennett,et al. IN-STENT STENOSIS: PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS , 2003, Heart.
[7] F. Crea,et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). , 2002, Journal of the American College of Cardiology.
[8] A. Gaspardone,et al. Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. , 2002, The American journal of cardiology.
[9] V. Hasselblad,et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. , 2002, Journal of the American College of Cardiology.
[10] L. Deckelbaum,et al. Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization , 2001, Circulation.
[11] C M Gibson,et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.
[12] E. Braunwald,et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. , 1999, Circulation.
[13] D Wybenga,et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.
[14] E. Braunwald,et al. TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.
[15] T Sandor,et al. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. , 1992, The American journal of cardiology.
[16] W. Ganz,et al. The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.
[17] F. Fedele,et al. Early elevation of interleukin-1beta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. , 2006, Thrombosis research.
[18] Harry,et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.
[19] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.